

Efferon® LPS

NEXT-GENERATION
EXTRACORPOREAL ADSORBER.
CE MARK UNDER EU MDR
REQUIREMENTS.

- Surface-modified hypercrosslinked polystyrene beads
- Direct removal of dissimilar therapeutic targets: endotoxins and cytokines
- Clinical benefits in sepsis patients validated in mRCT

INDICATIONS:


- Sepsis and septic shock.
- Elevated levels of endotoxin in blood, critical endotoxemia.
- Elevated levels of cytokines in blood, «cytokine storm» syndrome.

MODE OF ACTION:

Multimodal adsorbent beads selectively bind two dissimilar therapeutic targets: endotoxins and excess of inflammatory mediators (such as cytokines).

Bacterial endotoxins

Endotoxins are adsorbed via interaction with surface-immobilized synthetic LPS-selective ligand.



Cytokines and cell debris are adsorbed via intrinsic porosity of hypercrosslinked polystyrene matrix.

Cytokines and inflammatory mediators



OVERVIEW OF LASSO mRCT

Efferon LPS safety and efficacy was studied in LASSO mRCT (NCT 04827407), its results were published in Shock peer-reviewed journal. Patients with abdominal sepsis, complicated with septic shock (n=58) were randomized in two groups. Control group received standard of care treatment, intervention group received two Efferon LPS hemoperfusions.

KEY BENEFITS OF EFFERON LPS HEMOPERFUSION:

- Successful resolution of septic shock and restoration of systemic hemodynamic function with lower dosage of vasopressor drugs;
- More IMV- and RRT-free days;
- Multiple Organ Failure Syndrome faster resolution;
- Oxygen metabolism function improvement;
- Reduction of endotoxemia and systemic inflammation biomarkers levels;
- No hemoperfusion-related adverse effects, less than 2% premature circuit clotting occurrence.

